Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$1.51
$1.49
$0.20
$2.63
$10.35M1.58352,864 shs120,938 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.94
-1.0%
$1.84
$1.33
$2.89
$57.37M1.75412,369 shs148,789 shs
Mallinckrodt plc stock logo
MNK
Mallinckrodt
$0.34
$0.75
$6.42
$1.58MN/A2.62 million shs39,227 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$1.91
-12.4%
$1.92
$1.71
$20.28
$4.38M4.22163,599 shs26,808 shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$2.49
-5.7%
$2.07
$0.51
$3.22
$139.22M1.331.23 million shs1.01 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00%0.00%0.00%0.00%+5.59%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+3.70%+2.62%+5.95%+28.95%+1.55%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00%0.00%0.00%0.00%0.00%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-0.46%+5.83%+24.57%+2.35%-99.10%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-6.05%-8.97%-6.71%+254.65%+86.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.539 of 5 stars
3.51.00.00.02.23.30.6
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
3.9569 of 5 stars
3.33.00.04.72.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.00
N/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00982.47% Upside
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00
N/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
0.00
N/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.50
Moderate Buy$5.00100.80% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$19.98M0.52N/AN/A($5.51) per share-0.27
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.78M0.99N/AN/A($0.06) per share-32.33
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/A$47.48 per shareN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$8.04M0.55N/AN/A($3.66) per share-0.52
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$47.98M2.90N/AN/A$0.85 per share2.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
-$14.47M-$3.65N/AN/A-36.24%N/A-147.37%N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$8.27MN/A0.00N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)

Latest MNK, AGRX, SPRO, RDHL, and FBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.31N/AN/AN/A$14.53 millionN/A
8/4/2025Q2 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.35N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/A
0.56
0.38
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Mallinckrodt plc stock logo
MNK
Mallinckrodt
1.18
0.57
0.31
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.54
0.37
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A
2.56
2.56

Institutional Ownership

CompanyInstitutional Ownership
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
10.92%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
83.74%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%

Insider Ownership

CompanyInsider Ownership
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.50%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
27.90%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.30%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
5.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
306.86 million6.82 millionNot Optionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Mallinckrodt plc stock logo
MNK
Mallinckrodt
2,70013.17 million13.13 millionNot Optionable
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2102.30 million2.14 millionNo Data
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
15055.91 million52.84 millionOptionable

Recent News About These Companies

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agile Therapeutics stock logo

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.94 -0.02 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$1.95 +0.01 (+0.52%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Mallinckrodt stock logo

Mallinckrodt NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$1.91 -0.27 (-12.39%)
Closing price 03:59 PM Eastern
Extended Trading
$1.94 +0.03 (+1.57%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$2.49 -0.15 (-5.68%)
Closing price 04:00 PM Eastern
Extended Trading
$2.52 +0.03 (+1.41%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.